Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre [0.03%]
单一中心序贯ALK-TKI治疗的ALK阳性NSCLC患者的临床特征分析
Kohei Fujita,Takuma Imakita,Naoki Fujimoto et al.
Kohei Fujita et al.
Introduction: Although sequential treatment with ALK-TKIs for ALK-positive lung cancer is commonly practiced in clinical settings, there are few reports on the actual treatment choices, efficacy and safety. ...
Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK [0.03%]
英国艾乐替尼一线治疗ALK阳性晚期NSCLC患者脑转移的治疗成本分析
Hannah Le,Daniel Ladino,Chrissy Lowry et al.
Hannah Le et al.
Introduction: This study aimed to estimate the NHS costs of managing patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small-cell lung cancer (aNSCLC), with and without brain metastases. Patients were ...
Correction [0.03%]
改正措施
Published Erratum
Lung cancer management. 2026 Dec;15(1):2654211. DOI:10.1080/17581966.2026.2654211 2026
Surgical management of concomitant lung cancer and cardiovascular diseases: a multidisciplinary perspective [0.03%]
合并肺癌和心血管疾病的外科治疗：多学科视角
Ryu Kanzaki,Jiro Okami
Ryu Kanzaki
Lung cancer and cardiovascular diseases (CVDs) frequently coexist due to shared risk factors such as aging, smoking, and chronic inflammation. The growing prevalence of elderly surgical candidates with concomitant lung cancer and CVDs prese...
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer [0.03%]
替泊替尼与卡马替尼治疗MET外显子14跳变非小细胞肺癌二线患者的成本效益分析
Mengmeng Liu,Lu Zhong,Tong Liu
Mengmeng Liu
Background: This study evaluated the cost-effectiveness of Tepotinib versus Capmatinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with MET Exon 14 Skipping Mutations in China. ...
Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life [0.03%]
用于肺癌患者的立体定向体外放射治疗中添加脉冲电场消融对其健康相关生活质量的影响
Jeremy P Harris,Christina Boyd,Mengying Shi et al.
Jeremy P Harris et al.
Introduction: Treatment indications for oligometastatic/oligoprogressive lung tumors are growing. Safety and lack of detrimental effect on patients' quality of life are critical for novel local therapies. ...
CyberKnife radical cure for early lung adenocarcinoma: a case was confirmed by postoperative pathology [0.03%]
CyberKnife治疗早期肺腺癌一例(术后病理证实)
Tingting Wang,Jingjing Fan,Xiaoyan Lv et al.
Tingting Wang et al.
The utilization of pathological assessment to evaluate tumor response in patients with early-stage non-small cell lung cancer (NSCLC) has not been documented in the extant literature. A 64-year-old male patient with lung adenocarcinoma was ...
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China [0.03%]
中国ALK阳性晚期NSCLC一线TKI治疗患者脑转移的治疗成本分析研究
Bingqi Hu,Jing Xue,Dingsiman Li et al.
Bingqi Hu et al.
Aim: To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs). ...
Leveraging machine learning to predict de novo skin malignancy following lung transplantation [0.03%]
利用机器学习预测肺移植后皮肤恶性肿瘤的发生
Nasim Nosoudi,Amir Zadeh,Rayna Nichols et al.
Nasim Nosoudi et al.
Aims: This study aimed to predict post-transplant malignancy risks at multiple levels among lung transplant recipients using machine learning (ML) and to identify key clinical and immunogenetic predictors. ...
Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases [0.03%]
rucaparib治疗复发性含BRCA1/2胚系致病突变的恶性胸膜间皮瘤两例报道
Luigi Cerbone,Benedetta Del Rio,Sara Delfanti et al.
Luigi Cerbone et al.
Pleural mesothelioma is a rare disease with few therapeutic options, especially in the first line refractory setting. Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group o...